<DOC>
	<DOCNO>NCT00544999</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cytarabine daunorubicin , work different way stop growth cancer cell , either kill cell stop dividing . Everolimus may help cytarabine daunorubicin work well make cancer cell sensitive chemotherapy . Giving everolimus together cytarabine daunorubicin may kill cancer cell . PURPOSE : This phase I trial study side effect best dose everolimus give together cytarabine daunorubicin treat patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Everolimus , Cytarabine , Daunorubicin Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose everolimus . - Determine toxicity regimen . Secondary - Assess activation PI3K/AKT mTORC 1 leukemic blast . - Evaluate pharmacokinetics everolimus different concentration . OUTLINE : This multicenter study . Patients receive primary induction therapy comprise daunorubicin hydrochloride IV day 1-3 , cytarabine IV 24 hour day 1 , oral everolimus day 1 7 . Patients 5 % blast day 15 receive second induction course comprise daunorubicin hydrochloride IV day 17 18 cytarabine IV twice daily day 17-20 . After completion study therapy , patient follow 3 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Diagnosis de novo secondary acute myeloid leukemia meeting follow criterion : Relapse &gt; 1 year obtain complete remission ( prior treatment allow ) Exclusion criterion : Philadelphia chromosomepositive disease blast crisis FAB M3 , M6 , M7 disease PATIENT CHARACTERISTICS : Inclusion criterion : Life expectancy ≥ 4 week Transaminases ≤ 5 time normal Creatinine ≤ 2 time normal Bilirubin ≤ 3 time normal ( except visceral involvement present ) Alkaline phosphatase gammaglutamyltransferase ≤ 5 time normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 28 day completion study therapy Exclusion criterion : FEV1 &lt; 30 % Active uncontrolled viral pulmonary infection Serious psychiatric disorder related leukemia condition would prohibit comprehension study HIVpositive Other concurrent malignancy except noninvasive skin cancer carcinoma situ Patients incarcerated supervision trusteeship PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Exclusion criterion : Prior experimental medication within past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>